![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetics and Safety of Single Dose of the Monoclonal Antibody Tobevibart (VIR-3434) Administered as Monotherapy or in Combination with the Small Interfering RNA Elebsiran (VIR-2218) in Cirrhotic Participants with Mild Hepatic Impairment
|
|
|
EASL (European Association for the Study of the Liver), 5-8 June, 2024, Milan, Italy
Li Wang, Sneha V. Gupta, Michael A. Chattergoon, Asma El-zailik, Cheng Huang, George Hristopoulos, Maribel Reyes
Vir Biotechnology, Inc., San Francisco, CA
![0613241](../images/061424/061424-2/0613241.gif)
![0613242](../images/061424/061424-2/0613242.gif)
![0613243](../images/061424/061424-2/0613243.gif)
![0613244](../images/061424/061424-2/0613244.gif)
![0613245](../images/061424/061424-2/0613245.gif)
![0613246](../images/061424/061424-2/0613246.gif)
![0613247](../images/061424/061424-2/0613247.gif)
![0613248](../images/061424/061424-2/0613248.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|